预约演示

更新于：2025-11-01

Omeprazole

奥美拉唑

更新于：2025-11-01

概要

基本信息

简介Omeprazole是一种质子泵抑制剂(PPI)，常用于治疗胃肠道疾病，如胃食管反流病(GERD)、消化性溃疡和Zollinger-Ellison综合征。它通过抑制胃壁壁细胞产生胃酸来发挥作用。Omeprazole以口服剂型供应，患者通常耐受性良好。然而，可能会出现头痛、腹泻和腹痛等副作用。作为研究和开发研究人员，需要注意的是，目前正在研究Omeprazole在治疗哮喘和骨质疏松症等其他疾病方面的潜在用途，因为它在临床前和临床研究中显示出了良好的效果。这些研究的结果有望促进Omeprazole的进一步临床应用和发展。

药物类型

小分子化药

别名

Aomeilazuo Changrong Jiaonang、Omeprazole (JP17/USP/INN)、Omeprezole

+ [36]

靶点

Proton pump

作用方式

抑制剂

作用机制

质子泵抑制剂

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

Sandoz Pty Ltd.Taiyo Pharma Co., Ltd.

Mitsubishi Tanabe Pharma Corp.

+ [3]

非在研机构

AstraZeneca Pharmaceuticals LP

国药集团工业有限公司

Novartis Pharmaceuticals Corp.

+ [1]

权益机构

AstraZeneca PLC

CHEPLAPHARM Arzneimittel GmbH

最高研发阶段批准上市

首次获批日期

中国 (1988-12-31),

十二指肠溃疡内分泌腺肿瘤胃食管反流+ [2]

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构/序列

分子式C17H19N3O3S

InChIKeySUBDBMMJDZJVOS-UHFFFAOYSA-N

CAS号73590-58-6

关联

562

项与奥美拉唑相关的临床试验

NCT07214662

/ Not yet recruiting临床1期

A Phase Ia/Ib Dose-Escalation and Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Giredestrant in Patients With Locally Advanced Or Metastatic ER-Positive, HER2-Negative Breast Cancer Who Have Previously Progressed During or After CDK4/6 Inhibitor Therapy

This is a first-in-human, Phase Ia/Ib, dose-escalation and expansion study evaluating the safety, pharmacokinetics, and activity of GDC-0587 (cyclin-dependent kinase-4 [CDK4] inhibitor) as a monotherapy and in combination with giredestrant in participants with locally advanced or metastatic estrogen receptor-positive and human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer who have previously progressed during or after CDK 4/6 inhibitor therapy.

开始日期2025-11-01

申办/合作机构

Genentech, Inc.

NCT07149415

/ Completed临床1期

A Phase 1, Open-Label, Single-Sequence, 2-Period, Drug-Drug Interaction Study in Healthy Participants Evaluating the Effect of Omaveloxolone on the Pharmacokinetics of CYP2C19 Substrate, Omeprazole

In this study, researchers will learn more about BIIB141, also known as omaveloxolone or SKYCLARYS®. This drug has been approved, or made available for doctors to prescribe, for people with Friedrich's Ataxia (FA) who are at least 16 years old. This is called a "drug-drug interaction" study. In this kind of study, researchers are looking at what happens when 2 or more medicines affect each other in the body. This could change how 1 or both of the drugs work, either making them stronger, weaker, or causing health problems.
The main goal of this study is to learn if taking BIIB141 affects how omeprazole is processed in the body. Omeprazole is a commonly used medicine to help lower the amount of acid the stomach makes.
The main question researchers want to answer in this study is :
• How does the body process omeprazole when taken with BIIB141?
Researchers will also learn more about :
* How many participants have adverse events during the study. An adverse event is a health problem that may or may not be caused by the study drug.
* How many participants have adverse reactions during the study. An adverse reaction is a health problem that may be caused by the study drug.
* If there are any changes in the participants' overall health during the study.
This study will be done as follows:
* Participants will be screened to check if they can join the study. The screening period will be up to 28 days, after which participants will check into their study research center.
* Participants will stay at the study research center for about 17 days.
* This is an "open label" study. In this kind of study, the participants, study doctor, and site staff know which study drug the participant is taking. In this study, all participants took BIIB141 and omprezole.
* Participants will take omeprazole on Day 1 and Day 16. They will also take BIIB141 once a day from Day 2 through Day 16.
* Throughout the study, researchers will take participants' blood and urine samples. Researchers will also do other tests to check the participants' overall health and will ask participants how they are feeling.
* Each participant will be in the study for up to 45 days.

开始日期2025-09-02

申办/合作机构

Biogen, Inc.

NCT07142486

/ RecruitingN/AIIT

Effects of Omeprazole Ingestion on Postprandial Amino Acid Concentrations in Response to a Mixed Meal: A Pilot Study

Omeprazole is a proton pump inhibitor commonly used to reduce stomach acid in the treatment of heartburn, gastroesophageal reflux disease, and gastric ulcers. By blocking the H⁺/K⁺-ATPase pumps in the gastric lining, it raises gastric pH and can alter the normal activation of pepsin, the enzyme responsible for beginning protein breakdown in the stomach.
Under normal conditions, dietary proteins are denatured by gastric acid and cleaved by pepsin into smaller peptides. These peptides enter the small intestine, where pancreatic enzymes (trypsin, chymotrypsin) and brush-border peptidases (aminopeptidase, dipeptidase) further hydrolyze them into free amino acids that are absorbed into the bloodstream. Suppressing stomach acidity may allow larger peptides to pass into the intestine, potentially reducing the efficiency of amino acid liberation and absorption.
In this randomized, crossover study, adults aged 50-60 years will attend two study visits at least one week apart. In one visit they will take a standard dose of omeprazole before consuming a mixed meal with a fixed protein content; in the other visit they will consume the same meal without medication. Blood samples will be collected before the meal and at multiple time points afterward to measure plasma amino acid concentrations and compare postprandial responses.
Older adults experience anabolic resistance, meaning they require higher protein intakes to stimulate muscle protein synthesis effectively. If omeprazole reduces amino acid availability after a meal, individuals taking this medication may need adjusted dietary protein recommendations. Findings from this study will help refine nutrition guidelines for people on proton pump inhibitors and support optimal muscle health and recovery in middle-aged and older adults.

开始日期2025-09-01

申办/合作机构

McGill University

[+1]

100 项与奥美拉唑相关的临床结果

登录后查看更多信息

100 项与奥美拉唑相关的转化医学

登录后查看更多信息

100 项与奥美拉唑相关的专利（医药）

登录后查看更多信息

12,428

项与奥美拉唑相关的文献（医药）

2026-04-01·ARCHIVES OF MEDICAL RESEARCH

Pharmacogenetic Drug Administration and Community Health: A Cross-Sectional Telecommunication-Based Study

Article

作者: Repin, Alexey N ; Anfinogenova, Nina D ; Kuznetsova, Alina D ; Chesalov, Nazary P ; Stepanov, Vadim A ; Popov, Sergey V

PURPOSE:

Drugs are considered pharmacogenetic (PGx) when genetic variants impact their efficacy, metabolism, or toxicity due to drug-gene interactions. This study aimed to elucidate PGx drug intake patterns in population samples.

METHODS:

The Short Message Service (SMS) invitations were sent to randomly selected adult clients of a telecommunication company. A total of 2,149 respondents were enrolled. The online questionnaire included questions on demographic, clinical, pharmacological, behavioral, and other factors. PharmGKB resources were used to identify PGx genes potentially involved in pharmacotherapy outcomes. Proneness to adverse drug reactions (ADRs) was assessed based on the ADR index (ADRi).

RESULTS:

Most respondents (68.45%) were taking pharmacotherapy (433 drugs) associated with 839 PGx genes. The top five PGx drugs included bisoprolol, aspirin, losartan, indapamide, and omeprazole. The five most important PGx gene families involved in pharmacotherapy were CYP, UGT, SLC, IL, and HLA. The top five PGx genes were: CYP3A5, ABCB1, CYP2D6, CYP2C9, and ACE. The number of PGx genes per drug ranged from 0 to 138. A high number of PGx genes associated with pharmacotherapy were observed in patients with coronary artery disease, diabetes mellitus, endocrine diseases, dyssomnia, and rheumatic diseases. PGx burden significantly correlated with health conditions, median ADRi values, health-related behavioral traits, and clinical-pharmacology characteristics (p <0.001).

CONCLUSION:

The high prevalence of PGx drug utilization encourages the implementation of pre-emptive PGx testing. In the meantime, medical history taking, dose adjustment, assessment of drug blood concentrations, and committing to medical minimalism may prevent PGx-triggered ADRs.

2026-01-01·JOURNAL OF ETHNOPHARMACOLOGY

Metabolic enzyme-mediated pharmacokinetic and pharmacodynamic interactions between Danshen Yin and clopidogrel in normal and acute myocardial infarction rats

Article

作者: Li, Manlin ; Zhang, Sitong ; Xie, Xueqing ; Cheng, Xuemei ; Zeng, Xin ; Wang, Changhong ; Liu, Wenkang ; Lei, Jinchun ; Xiang, Zedong ; Gao, Xuan ; Hu, Xianrun

ETHNOPHARMACOLOGICAL RELEVANCE:

Danshen Yin (DSY) as a traditional Chinese medicine (TCM) formula, has been extensively employed as a clinical adjuvant in the treatment of cardiovascular diseases, particularly acute myocardial infarction (AMI). Clinical benefits of the combined use of DSY and clopidogrel (Clop) have been documented, yet the mechanism of the combination therapy is still obscure and the herb-drug interactions (HDIs) on pharmacokinetic and pharmacodynamic of DSY and Clop is unclear.

AIM OF THE STUDY:

This study aims to elucidate the pharmacokinetic and pharmacodynamic interactions between DSY and Clop, with a focus on metabolic enzyme regulation, to provide mechanistic insights into their combined therapeutic efficacy in myocardial infarction treatment.

MATERIALS AND METHODS:

AMI rat model was established to explore therapeutic effects and pharmacodynamic interactions between DSY and Clop after co-administrations. Then, a rapid, sensitive and reliable UPLC-MS/MS method was developed to determine the dose-related pharmacokinetic interactions between DSY and Clop. Subsequently, the effect of DSY on CYP450 (CYP1A2, CYP2C19, CYP2C9, CYP3A4) and carboxylesterases 1 (CES1) were investigated by cocktail and bioluminescence assays. Finally, primary hepatocytes isolated from rats were utilized to investigate the effects of DSY, its individual herbal components and active constituents on the mRNA expression of the Clop key metabolic enzymes to elucidate the underlying mechanism of HDIs.

RESULTS:

Compared with the monotherapy groups, the combination therapy of DSY with Clop significantly enhanced cardiac function, mitigated pathological damage in cardiac tissue, regulated coagulation indicators, suppressed the maximum platelet aggregation ratio, and led to a decrease in the serum levels of CK-MB, vWF, TXB₂ and β-TG, while increasing the level of 6-Keto-PGF_1α. Besides, the combination of DSY and Clop had no obvious influence on the pharmacokinetic behaviors of the bioactive components of DSY (salvianolic acid B, salvianolic acid A, and danshensu), but significantly altered AUC_0-t and AUC_0-∞ of Clop and clopidogrel active metabolite derivatized (CAMD) in normal and AMI model rats. Correspondingly, the systemic exposure of CAMD relative to that of Clop was increased. DSY was inclined to promote the metabolism of tolbutamide (CYP2C9 substrate) and omeprazole (CYP2C19 substrate), and upregulated the mRNA levels of CYP2C11 and CYP2C22 in rats. Among the main active ingredients of Salvia miltiorrhiza Bunge, the monarch drug in DSY, salvianolic acid B, salvianolic acid A, tanshinone II_A, cryptotanshinone and tanshinone I elevated the mRNA expression levels of CYP2C11 and CYP2C22.

CONCLUSIONS:

Herein, the pharmacokinetic and pharmacodynamic interactions between DSY and Clop were investigated, revealing the promotion of metabolic activation of Clop through DSY bioactive constituents (e.g., salvianolic acid B, salvianolic acid A, tanshinone II_A, cryptotanshinone, tanshinone I) for the first time. This observation is not only expected to provide a new reference and perspective for the synergistic therapy of DSY and Clop, but also served as a helpful strategy of HDIs assessment.

2026-01-01·TALANTA

Programmable flow heart cutting solid phase extraction using polydopamine coated microfibrous sorbent as a front-end to UHPLC for direct determination of xenobiotic residues in surface water

Article

作者: Erben, Jakub ; Chocholouš, Petr ; Šatínský, Dalibor ; Holec, Pavel ; Chocholoušová Havlíková, Lucie ; Švec, František

Automation and hyphenation of multiple steps were used for the sensitive determination of xenobiotic residues in surface waters. The online hyphenated sequential injection analysis instrumentation used surface-modified microfibrous sorbent for the effective solid phase extraction of 1.0 mL of sample into 100 μL zone, then subjected to the reversed-phase ultra-high performance liquid chromatography (SIA-SPE-UHPLC). The SPE column was packed with polypropylene microfibers and coated with polydopamine by rinsing with the dopamine solution. The freshly prepared column was used for highly reproducible extraction of more than 200 samples in the SIA-SPE-UHPLC method. The matrix calibration covered the expected range with limits of detection in the range 0.1-0.9 μg/L. The method precision was <13 % RSD (at 3 concentration levels), and the method accuracy was in the range 86.5-114.8 %. The sample throughput of the method was 5 samples/hour when the separation took 12 min, including a 5 min SPE step of the next sample run in parallel. The performance of the developed method was demonstrated with the analysis of fifteen river water samples spiked with eleven residues of xenobiotics (ivermectin, fenbendazole, praziquantel, ibuprofen, diclofenac, 17α-ethynylestradiol, androstenedione, carbamazepine, omeprazole, sotalol, and caffeine) at the levels typical for such monitoring. Initial sample treatment prior to the automated analysis consisted only of methanol addition, pH adjustment, and centrifugation. The innovations in the manifold and process that contribute to the modern and effective analysis of environmental samples are discussed.

432

项与奥美拉唑相关的新闻（医药）

2025-10-30

·手机新浪网

悦康药业跌0.82%，成交额9612.16万元，近3日主力净流入-1026.93万

10月30日，悦康药业跌0.82%，成交额9612.16万元，换手率1.04%，总市值92.66亿元。异动分析创新药+细胞免疫治疗+仿制药一致性评价+幽门螺杆菌概念+人工智能1、根据2025年3月15日公告：各项创新药研发进程加速推进的同时，公司在研发领域也取得了重大突破性成果。如：重点研发项目——靶向PCSK9的siRNA 1.1类创新药YKYY015注射液，成功获得了发明专利授权。这一里程碑式的成就，不仅彰显了公司在创新药物研发方面的雄厚实力和卓越能力，也为后续的临床试验和市场推广奠定了坚实基础。2、根据2025年3月15日公告：公司有自主研发的细胞与基因治疗药物开发平台，本平台具备先进的CAR设计技术，运用CRISPR/C as9基因编辑实现精准改造。通过实体瘤靶点筛选及双靶点CAR结构创新，开发双靶点CAR-T、CAR-NK 疗法。利用FASTCART平台技术降低成本、缩短制备周期，借助流式细胞术保证细胞筛选和质量。同时，结合mRNA-LNP 技术前瞻性布局in vivo细胞疗法。3、2024年2月6日互动易回复，截止2024年1月，公司共15项产品已通过仿制药一致性评价。4、公司拟投资 10,000.00 万元建设新的原料药生产线。项目建成后，达产年生产能力为双氯芬酸钠年产 330 吨、兰索拉唑年产 10吨，来曲唑年产 0.30 吨。兰索拉唑为一种新型抑制胃酸分泌药物，对幽门螺杆菌的抑菌活性比奥美拉唑较高。5、2023年年报：在人工智能药物开发方面，公司搭建了多个AI深度学习模型，可用于靶标发现、药物设计、药物筛选、化学合成、工艺开发及参数优化等全链条药物研发环节。用于多肽、阳离子脂质、肿瘤新抗原等药物的全新设计，以及药物活性和毒性筛选，并已向国家知识产权局提交4项AI药物算法专利。公司借助已开发的AI算法模型可以实现药物的从头设计，已设计出多个候选分子并正在系统地进行实验验证，这将高效地缩短药物设计和筛选进程，提升药物研发的效率。(免责声明：分析内容来源于互联网，不构成投资建议，请投资者根据不同行情独立判断)资金分析今日主力净流入-186.17万，占比0.02%，行业排名60/159，连续3日被主力资金减仓；所属行业主力净流入-23.12亿，连续3日被主力资金减仓。区间今日近3日近5日近10日近20日主力净流入-186.17万-1026.93万-1584.09万-2816.75万-3088.07万主力持仓主力没有控盘，筹码分布非常分散，主力成交额2437.91万，占总成交额的4.39%。技术面：筹码平均交易成本为25.55元该股筹码平均交易成本为25.55元，近期筹码减仓，但减仓程度减缓；目前股价靠近压力位21.12，谨防压力位处回调，若突破压力位则可能会开启一波上涨行情。公司简介资料显示，悦康药业集团股份有限公司位于北京市北京经济技术开发区宏达中路6号，成立日期2001年8月14日，上市日期2020年12月24日，公司主营业务涉及悦康药业定位于高端化学药的研发与生产,报告期内主营业务收入主要集中在心脑血管药物、消化系统药物、糖尿病用药以及抗感染药物等。银杏叶提取物注射液、天麻素注射液、注射用兰索拉唑、奥美拉唑肠溶胶囊、盐酸二甲双胍缓释片、注射用头孢呋辛钠、注射用头孢曲松钠对公司收入贡献占比较大或未来增长潜力较大,是公司的主要产品。主营业务收入构成为：心脑血管类55.67%，抗感染20.88%，原料药8.73%，消化系统类6.87%，降糖类4.85%，其他2.62%，其他(补充)0.36%，技术服务0.02%。悦康药业所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：幽门螺杆概念、创新药、中药、AI医药、医药电商等。截至9月30日，悦康药业股东户数1.07万，较上期减少8.39%；人均流通股42095股，较上期增加9.16%。2025年1月-9月，悦康药业实现营业收入17.59亿元，同比减少41.20%；归母净利润-1.48亿元，同比减少170.56%。分红方面，悦康药业A股上市后累计派现10.92亿元。近三年，累计派现5.84亿元。机构持仓方面，截止2025年9月30日，悦康药业十大流通股东中，富国精准医疗灵活配置混合A（005176）位居第五大流通股东，持股1077.41万股，相比上期减少33.70万股。易方达医疗保健行业混合A（110023）位居第六大流通股东，持股976.65万股，相比上期增加291.14万股。富国医药创新股票A（019916）位居第九大流通股东，持股683.22万股，为新进股东。富国天博创新混合（519035）位居第十大流通股东，持股632.26万股，为新进股东。南方医药保健灵活配置混合A（000452）退出十大流通股东之列。风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建议。

细胞疗法免疫疗法信使RNA

2025-10-29

·网易号

悦康药业跌0.05%，成交额1.32亿元，今日主力净流入-838.65万

来源：证券-红岸工作室10月29日，悦康药业跌0.05%，成交额1.32亿元，换手率1.42%，总市值93.42亿元。异动分析创新药+细胞免疫治疗+仿制药一致性评价+幽门螺杆菌概念+人工智能1、根据2025年3月15日公告：各项创新药研发进程加速推进的同时，公司在研发领域也取得了重大突破性成果。如：重点研发项目——靶向PCSK9的siRNA 1.1类创新药YKYY015注射液，成功获得了发明专利授权。这一里程碑式的成就，不仅彰显了公司在创新药物研发方面的雄厚实力和卓越能力，也为后续的临床试验和市场推广奠定了坚实基础。2、根据2025年3月15日公告：公司有自主研发的细胞与基因治疗药物开发平台，本平台具备先进的CAR设计技术，运用CRISPR/C as9基因编辑实现精准改造。通过靶点筛选及双靶点CAR结构创新，开发双靶点CAR-T、CAR-NK 疗法。利用FASTCART平台技术降低成本、缩短制备周期，借助流式细胞术保证细胞筛选和质量。同时，结合mRNA-LNP 技术前瞻性布局in vivo细胞疗法。3、2024年2月6日互动易回复，截止2024年1月，公司共15项产品已通过仿制药一致性评价。4、公司拟投资 10,000.00 万元建设新的原料药生产线。项目建成后，达产年生产能力为双氯芬酸钠年产 330 吨、兰索拉唑年产 10吨，来曲唑年产 0.30 吨。兰索拉唑为一种新型抑制胃酸分泌药物，对幽门螺杆菌的抑菌活性比奥美拉唑较高。5、2023年年报：在人工智能药物开发方面，公司搭建了多个AI深度学习模型，可用于靶标发现、药物设计、药物筛选、化学合成、工艺开发及参数优化等全链条药物研发环节。用于多肽、阳离子脂质、肿瘤新抗原等药物的全新设计，以及药物活性和毒性筛选，并已向国家知识产权局提交4项AI药物算法专利。公司借助已开发的AI算法模型可以实现药物的从头设计，已设计出多个候选分子并正在系统地进行实验验证，这将高效地缩短药物设计和筛选进程，提升药物研发的效率。(免责声明：分析内容来源于互联网，不构成投资建议，请投资者根据不同行情独立判断)资金分析今日主力净流入-838.65万，占比0.06%，行业排名117/159，连续3日被主力资金减仓；所属行业主力净流入-6.59亿，连续2日被主力资金减仓。区间今日近3日近5日近10日近20日主力净流入-838.65万-1066.57万-1733.85万-504.11万-2364.82万主力持仓主力没有控盘，筹码分布非常分散，主力成交额2587.67万，占总成交额的5.47%。技术面：筹码平均交易成本为25.60元该股筹码平均交易成本为25.60元，近期筹码减仓，但减仓程度减缓；目前股价靠近压力位21.12，谨防压力位处回调，若突破压力位则可能会开启一波上涨行情。公司简介资料显示，位于北京市北京经济技术开发区宏达中路6号，成立日期2001年8月14日，上市日期2020年12月24日，公司主营业务涉及悦康药业定位于高端化学药的研发与生产,报告期内主营业务收入主要集中在心脑血管药物、消化系统药物、糖尿病用药以及抗感染药物等。银杏叶提取物注射液、天麻素注射液、注射用兰索拉唑、奥美拉唑肠溶胶囊、盐酸二甲双胍缓释片、注射用头孢呋辛钠、注射用头孢曲松钠对公司收入贡献占比较大或未来增长潜力较大,是公司的主要产品。主营业务收入构成为：心脑血管类55.67%，抗感染20.88%，原料药8.73%，消化系统类6.87%，降糖类4.85%，其他2.62%，其他(补充)0.36%，技术服务0.02%。悦康药业所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：幽门螺杆概念、创新药、中药、AI医药、医药电商等。截至6月30日，悦康药业股东户数1.17万，较上期减少20.85%；人均流通股38563股，较上期增加26.33%。2025年1月-6月，悦康药业实现营业收入11.67亿元，同比减少40.14%；归母净利润-9882.91万元，同比减少183.36%。分红方面，悦康药业A股上市后累计派现10.92亿元。近三年，累计派现5.84亿元。机构持仓方面，截止2025年6月30日，悦康药业十大流通股东中，富国精准医疗灵活配置混合A（005176）位居第五大流通股东，持股1111.11万股，相比上期增加361.00万股。南方医药保健灵活配置混合A（000452）位居第六大流通股东，持股726.77万股，持股数量较上期不变。易方达医疗保健行业混合A（110023）位居第八大流通股东，持股685.51万股，为新进股东。风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建议。

细胞疗法免疫疗法信使RNA

2025-10-28

·小牛医典

安全用药 | 高级别浆液性癌安全用药指南

化疗药物在妇科恶性肿瘤的治疗中经常会用到，尤其针对高级别浆液性癌这样的情况，安全用药细节更是每一步都不能忽视。本文整理了这类化疗全流程涉及的药品信息，包括常用化疗药、辅助药、生物制剂，帮你快速记住用药要求、注意重点，规避常见风险。图片由AI生成 1 剂型与规范用法化疗药（如紫杉醇、多西他赛、顺铂/卡铂）通常为静脉注射剂型，必须在医院由专业人员操作，不能自行使用。辅助药如止吐药（如昂丹司琼、托烷司琼/格拉司琼）多为片剂或注射液。片剂按医嘱定时口服；注射剂需专业配液。护胃药（如质子泵抑制剂奥美拉唑）为片剂，通常化疗同日或前一晚开始服用，每日一次，餐前半小时服用效果更好。生物制剂（如贝伐珠单抗、帕姆单抗、奥拉帕利等）多为静脉注射或口服片剂，具体药物需严格遵循说明书及医生指导，不能随意停减。正确做法：所有药品首次使用、换方案或换品牌时，一定仔细核对剂型与外观，发现异常应立即报告。 2 给药时间与用法化疗注射需根据方案周期，一般每3周一次，具体间隔依药品方案和身体恢复情况，由医生决定。止吐药通常在化疗前30分钟至1小时使用，主要目标是预防恶心和呕吐。护胃药早晨空腹服用，有助于最大化保护胃黏膜，避免化疗相关胃刺激。部分生物制剂口服后需要餐前或餐后等特殊要求。举例：奥拉帕利要求空腹或进餐后2小时服用，不能与高脂高蛋白食物同服。正确做法：严格记录药品开始时间和结束时间，每次用药前再次核查方案及当日身体状况。 3 药品机制与重点成分解析铂类药物（如顺铂、卡铂）：通过干扰DNA复制与修复，阻断肿瘤细胞分裂，被广泛用于高级别浆液性癌的治疗。紫杉类（紫杉醇、多西他赛）：可稳定微管结构，防止细胞有丝分裂。常与铂类联合用药。止吐药（如昂丹司琼、托烷司琼）：属于5-HT3受体拮抗剂，可以有效抑制呕吐反射中枢。护胃药（如奥美拉唑）：抑制胃酸分泌，减少胃黏膜损伤风险。生物制剂：贝伐珠单抗抑制肿瘤血管生成，奥拉帕利抑制PARP酶，影响细胞修复。需要注意：不同药品机制决定了其主要副作用和使用禁忌，后面章节会详细说明。 4 用药案例与实践教训 📝 一位70岁女性在化疗第6周期时出现轻度血小板下降，经调整辅助药物后恢复正常，说明定期检测血象和灵活调整用药非常重要（不能自行增减剂量）。临床上常见患者因未按要求定时服用止吐药，导致化疗后恶心加重。因此每一周期止吐药必须严格按时投用。患者应用生物制剂时偶有轻度反应，如皮疹或胃部不适，随即报告医生后调整用药方案，大多数可安全继续使用。以上仅为用药情况总结，仍需根据自己的具体药品和方案与医生充分沟通。 5 药物相互作用与避免风险化疗药物与其他药品（如降压药、抗凝剂、糖皮质激素等）存在相互作用，使用期间如需合并其他药物，务必提前告知医生。说明书提示：昂丹司琼与阿莫达非尼等药合用时，可能增加心律异常风险。贝伐珠单抗与止血类药物或抗血小板药联合时需特别警惕出血风险。部分药品（如奥美拉唑）影响肝脏酶活性，可能改变生物制剂或其他口服药品的作用强度。每种新药或原有药品搭配时，都应核查相互作用，发现异常随时报告。 6 主要不良反应与处理原则化疗药常见副作用包括血小板下降、恶心、脱发，部分患者会出现肝肾功能异常。止吐药偶见头痛、便秘、心律改变，如有持续不适应暂停并及时就医。护胃药应用过程中少数人会出现胃胀、腹泻。生物制剂偶发皮疹、轻度过敏、血压升高等，如发现皮肤瘙痒、呼吸困难等严重反应必须立即就医。出现任何不良反应后，非急重症可以先暂停相关药物，等待医生处理决定，切忌自行处理。临床数据：高级别浆液性癌临床化疗方案中，骨髓抑制证发生率约为30%，需每周期监测血象。图片由AI生成 7 储存方法与有效期管理所有片剂、胶囊药需避光、防潮、25℃以下保存。切勿放在卫生间或阳光直射处。注射剂药品需按说明书冷藏或常温存放，开封后应及时用完，不宜长时间存储。种植细胞药、生物制剂等需专业冷藏，家用冰箱易温差大，请不要自存。过期药品要单独标识，及时丢弃，禁止随意服用或混用。正确做法：每月检查药箱，按批号与有效期分组，发现破损包装立即更新。 8 特殊人群用药技巧及剂量调整老年患者（如本次案例70岁）应根据身体状况调整化疗及辅助药品剂量，尤其注意肾功能变化。孕期哺乳期禁用大多数化疗药、生物制剂及部分止吐药。原则上此类方案仅限非常特殊情况，由医生严格评估。儿童基本不使用同类化疗药，仅在罕见特殊适应症下，剂量需严格按体重、体表面积计算。肝肾功能不全者所有药品剂量均需个体化调整，并频繁监测。不能自行换药或减药，如发现新问题需主动报告医生后处理。 9 漏服/过量补救办法辅助药物如止吐药漏服后，可以尽快补服一次，不可重复服用或加倍剂量。化疗药、生物制剂一旦漏用/错用，必须及时告知医生，由医生调整整体方案，不可自行接续。过量服药可能带来明显毒副作用，尤其是化疗药和生物制剂出现呼吸困难、皮疹、发热、头晕等症状时，应立即前往医院就诊。正确做法：用药期间，制定完整用药、检验和报告流程，建议使用电子日历或纸质管理卡辅助记录。总结来看，针对高级别浆液性癌的化疗及辅助治疗，药品应用环节细致合理，风险可控。 📚 参考文献： 1.Lord, J., Church, D. N., & McNeish, I. A. (2022). Efficacy and toxicity of platinum-based chemotherapy in high-grade serous ovarian and fallopian tube carcinoma. Journal of Clinical Oncology, 40(18), 2041–2052. PubMed 2.Ledermann, J. A., Colombo, N., Oza, A. M., et al. (2020). PARP inhibitors in ovarian/fallopian tube cancer: Mechanisms and clinical experience. The Lancet Oncology, 21(7), 924-934. PubMed 3.Gralla, R. J., et al. (2018). Efficacy and safety of 5-HT3 receptor antagonists in chemotherapy-induced nausea and vomiting. Supportive Care in Cancer, 26(1), 451-456. PubMed 科普作者华晓萍主治医师浙江大学医学院附属妇产科医院往期 · 推荐安全用药 | 急性髓系白血病用药解读：阿扎胞苷与维耐克拉用药指南安全用药 | 了解药物滥用障碍安全用药 | 走出焦虑的阴霾：药物治疗方法全解析内容出品温馨提示：本文中所涉及的信息旨在传递健康科普知识，不涉及诊疗方案推荐，临床上请遵从医生或其他医疗卫生专业人士的意见与指导。内容图源：本文图源网络侵删责任编辑：小牛医典版权声明科普作品著作权均属作者本人，并经作者本人授权在小牛医典进行宣传与发布。欢迎个人转发分享，其他任何媒体、网站如需转载须获得授权，且在醒目位置处注明「转自：小牛医典]

放射疗法

100 项与奥美拉唑相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00455	奥美拉唑	A02BC01	DB00338

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
胃灼热	美国	Dexcel Pharma Technologies Ltd.	2017-07-05
良性胃溃疡	美国	AstraZeneca Pharmaceuticals LP	2004-02-23
糜烂性食管炎	澳大利亚	Sandoz Pty Ltd.	2001-12-20
吻合口溃疡	日本	Mitsubishi Tanabe Pharma Corp.	1991-01-18
反流性食管炎	日本	Mitsubishi Tanabe Pharma Corp.	1991-01-18
消化性溃疡	日本	Taiyo Pharma Co., Ltd.	1991-01-18
腺癌	美国	AstraZeneca Pharmaceuticals LP	1989-09-14
幽门螺杆菌感染	美国	AstraZeneca Pharmaceuticals LP	1989-09-14
系统性肥大细胞增多症	美国	AstraZeneca Pharmaceuticals LP	1989-09-14
十二指肠溃疡	中国	AstraZeneca PLC	1988-12-31
内分泌腺肿瘤	中国	AstraZeneca PLC	1988-12-31
胃食管反流	中国	AstraZeneca PLC	1988-12-31
胃溃疡	中国	AstraZeneca PLC	1988-12-31
Zollinger-Ellison综合征	中国	AstraZeneca PLC	1988-12-31

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
上消化道出血	临床3期	中国	AstraZeneca PLC	2006-08-01
非糜烂性胃食管反流病	临床3期	日本	AstraZeneca PLC	2003-10-01
非糜烂性胃食管反流病	临床3期	日本	Mitsubishi Tanabe Pharma Corp.	2003-10-01
非糜烂性反流病	临床3期	日本	AstraZeneca PLC	2003-10-01
非糜烂性反流病	临床3期	日本	Mitsubishi Tanabe Pharma Corp.	2003-10-01
早期胃癌	临床1期	中国	国药集团工业有限公司	2020-06-13
胃泌素瘤	临床1期	中国	国药集团工业有限公司	2020-06-13
幽门螺杆菌相关性胃炎	临床1期	中国	国药集团工业有限公司	2020-06-13
边缘区B细胞淋巴瘤	临床1期	中国	国药集团工业有限公司	2020-06-13
免疫性血小板减少症	临床1期	中国	国药集团工业有限公司	2020-06-13

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05741385 (CTgov)	N/A	纤维化 \| 肝硬化	4	warfarin sodium+warfarin+omeprazole+metoprolol+midazolam+caffeine	鏇夢網願醖膚餘醖遞壓(簾鑰繭顧製襯繭淵艱鹽) = 遞齋鑰顧衊壓壓構選襯膚醖衊鏇憲窪廠醖獵襯 (願艱鏇獵簾壓醖憲鹹蓋, 37.3) 更多	-	2025-09-10
NCT03551691 (CTgov)	临床2期	胰腺外分泌功能不全 \| 囊性纤维化	19	Omeprazole 20mg Capsule (Omeprazole)	餘憲窪製築選窪鹹獵艱(繭鏇鹹築網壓夢憲獵範) = 願壓餘觸鏇構廠築簾齋壓鹹繭廠齋窪窪鹽鑰願 (壓積選膚構憲顧廠艱襯, 20) 更多	-	2024-04-30
				Placebo oral capsule (Placebo)	餘憲窪製築選窪鹹獵艱(繭鏇鹹築網壓夢憲獵範) = 膚觸蓋積憲糧淵蓋遞選壓鹹繭廠齋窪窪鹽鑰願 (壓積選膚構憲顧廠艱襯, 16) 更多
NCT02950259 (P212, CTgov)	临床1期	男性乳腺肿瘤 \| 三阴性乳腺癌 \| 早期乳腺癌	16	Multivitamin+Indomethacin+Omeprazole+Cyclophosphamide (IRX-2 Regimen -Early Stage Breast Cancer)	遞鹹廠構齋廠艱鏇遞鬱 = 構製構艱築齋鏇遞齋淵觸淵廠艱糧觸壓鑰廠選 (蓋選願範觸鏇醖網網鹽, 艱繭鬱鏇齋糧齋齋憲衊 ~ 獵範願壓餘獵築積觸繭) 更多	-	2024-01-30
				Multivitamin+Indomethacin+Omeprazole+Cyclophosphamide (IRX-2 Regimen -Triple Negative Breast Cancer)	遞鹹廠構齋廠艱鏇遞鬱 = 觸鹽觸構築憲壓淵簾齋觸淵廠艱糧觸壓鑰廠選 (蓋選願範觸鏇醖網網鹽, 製夢繭齋獵憲積膚鏇廠 ~ 蓋廠衊餘願選範選壓範) 更多
NCT02016820 (CTgov)	N/A	艰难梭菌感染	7	Omeprazole (Omeprazole (Suspension))	蓋淵淵衊糧廠繭壓襯蓋(簾艱遞壓襯鹹鑰築鹹襯) = 蓋窪夢鏇範獵夢築廠鬱網鏇蓋齋醖積積衊願選 (蓋鹽網鬱獵糧獵齋範艱, 膚蓋鑰齋鹽遞製繭鑰膚 ~ 遞蓋鬱艱築簾築積選膚) 更多	-	2023-12-26
				Lifestyle Modification (Lifestyle Modification)	蓋淵淵衊糧廠繭壓襯蓋(簾艱遞壓襯鹹鑰築鹹襯) = 鬱窪餘鏇壓夢遞積顧壓網鏇蓋齋醖積積衊願選 (蓋鹽網鬱獵糧獵齋範艱, 襯鬱製艱遞顧積構鹹齋 ~ 網鹽衊淵糧鏇壓選積顧) 更多
NCT05319912 (CTgov)	临床1期	-	18	ALXN1840 (Treatment A: ALXN1840 (Fasted))	鑰憲膚鑰鏇製顧齋襯獵(鑰廠窪襯蓋鹹鹽鏇築壓) = 膚構夢網淵選夢網齋壓憲蓋鏇蓋齋憲鬱襯積餘 (鏇膚遞壓觸壓願醖簾襯, 5635) 更多	-	2023-08-02
				ALXN1840 (Treatment B: ALXN1840 (Fed))	鑰憲膚鑰鏇製顧齋襯獵(鑰廠窪襯蓋鹹鹽鏇築壓) = 製構鬱鹹糧襯鏇襯鹽淵憲蓋鏇蓋齋憲鬱襯積餘 (鏇膚遞壓觸壓願醖簾襯, 4681) 更多
NCT05319899 (CTgov)	临床1期	-	18	ALXN1840 (Treatment A: ALXN1840 (Fasted))	遞繭鹹夢製鑰築簾願積(蓋壓齋齋築淵築廠醖膚) = 壓選範觸膚築簾襯襯網蓋鏇膚範製積衊構製遞 (淵夢夢鏇齋糧築夢觸憲, 6886) 更多	-	2023-08-01
				Omeprazole+ALXN1840 (Treatment B: Omeprazole + ALXN1840 (Fasted))	遞繭鹹夢製鑰築簾願積(蓋壓齋齋築淵築廠醖膚) = 遞積鬱艱製網餘願觸蓋蓋鏇膚範製積衊構製遞 (淵夢夢鏇齋糧築夢觸憲, 4303) 更多
NCT05342532 (CTgov)	临床4期	幽门螺杆菌感染	112	Omeprazole+Amoxicillin (High Dose Dual Therapy)	鑰衊艱觸壓衊製鏇鹽齋 = 襯觸網築廠齋願膚構簾憲鬱膚蓋鬱衊襯鏇淵遞 (範顧膚憲膚膚遞選窪窪, 壓醖夢壓壓鑰夢獵壓獵 ~ 獵夢壓鑰壓構構製鏇鹽) 更多	-	2023-02-01
				Omeprazole+Amoxicillin+Clarithromycin (Standard Triple Therapy)	鑰衊艱觸壓衊製鏇鹽齋 = 鹽鏇鹹繭齋衊醖鏇範鑰憲鬱膚蓋鬱衊襯鏇淵遞 (範顧膚憲膚膚遞選窪窪, 築膚糧廠鑰積網壓鹽壓 ~ 襯鬱積壓膚網鹹繭艱襯) 更多
Corporate Publications 人工标引	N/A	消化道出血	359	Omeprazole+Sodium Bicarbonate	齋艱艱憲積糧窪夢窪窪(簾鬱顧網遞網築構艱艱) = 製鑰糧淵觸窪蓋顧繭醖選襯艱繭觸顧壓繭鏇遞 (壓網構蓋鬱觸鹽獵壓壓 )	积极	2022-08-30
				Cimetidine	齋艱艱憲積糧窪夢窪窪(簾鬱顧網遞網築構艱艱) = 願廠網鏇築繭餘遞鹽選選襯艱繭觸顧壓繭鏇遞 (壓網構蓋鬱觸鹽獵壓壓 )
NCT04198948 (INTERGLIKOM, CTgov)	临床1期	2型糖尿病	15	Omeprazole+Gliclazide (Gliclazide + Omeprazole)	膚遞鏇窪網觸餘鑰築鑰(廠襯齋鬱淵構製夢觸鹽) = 膚夢鏇蓋築餘襯壓衊餘築壓積夢觸膚壓願製鏇 (蓋餘顧鹹壓積齋獵膚窪, 醖網築夢選糧蓋鏇鬱襯 ~ 願簾廠顧鏇廠淵夢獵蓋) 更多	-	2021-07-15
				Placebo+Gliclazide (Gliclazide + Placebo)	膚遞鏇窪網觸餘鑰築鑰(廠襯齋鬱淵構製夢觸鹽) = 窪繭觸鬱鹽繭蓋衊遞蓋築壓積夢觸膚壓願製鏇 (蓋餘顧鹹壓積齋獵膚窪, 艱獵積願構網鬱遞憲夢 ~ 築膚醖醖廠選簾簾遞鬱) 更多
ASN2020	临床1期	-	46	Veverimer	窪範壓鬱壓蓋糧願鑰繭(鏇顧餘憲觸醖膚構構構) = 廠齋網鬱選簾壓簾鹽鏇構廠製衊鏇網鏇製顧壓 (鹽醖艱獵簾壓齋壓製選 )	积极	2020-10-19
				Omeprazole	窪範壓鬱壓蓋糧願鑰繭(鏇顧餘憲觸醖膚構構構) = 憲壓鑰餘繭鏇築觸構觸構廠製衊鏇網鏇製顧壓 (鹽醖艱獵簾壓齋壓製選 )